New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 25, 2014
10:32 EDTIMMVFImmunoVaccine announces 'positive' results from Ebola vaccine study
Immunovaccine announced "positive" results for a vaccine formulated in its DepoVax technology in an Ebola virus challenge study performed by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. In a preliminary study using cynomolgus monkeys, which are particularly sensitive to the Ebola virus, all vaccinated subjects survived exposure to a lethal dose of the wild type Zaire strain of the virus. All unvaccinated control animals succumbed to the disease. In this study four cynomolgus macaque subjects received two doses of the DepoVax-formulated vaccine, one at study initiation and a second on Day 56. They were then challenged on day 70 with a lethal dose of the wild type Zaire strain of the Ebola virus. More than two weeks following exposure to the virus, all vaccinated subjects were alive with no disease symptoms. The two control animals in this study succumbed to the infection within seven days. Immunovaccine is preparing for a clinical trial with a DepoVax-based vaccine against respiratory syncytial virus planned for 2014.
News For IMMVF From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for IMMVF

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use